- Monsanto Co.
- Takeda Oncology
- Novartis AG
- Zeneca Group PLC
- Schering-Plough Corp.
- Dow Chemical Co.
- WR Grace & Co.
- Pfizer Inc.
- Eli Lilly & Co.
- Millennium BioTherapeutics Inc.
- Millennium Predictive Medicine Inc.
- Massachusetts Institute of Technology
- Incyte Corp.
- GD Searle & Co.
- Vertex Pharmaceuticals LLC
- Accelrys Inc.
- ArQule Inc.
- Human Genome Sciences Inc.
- BASF SE
- SmithKline Beecham
- Bayer AG
- Synteni Inc.
- Affymetrix Inc.
- Scripps Research Institute
- ValiGen Inc.
- CuraGen Corp.
- Monsanto pays $218mm in genomics pact with Millennium
- Astra in 5-year genomic research deal with Millennium
- Millennium Pharmaceuticals acquires ChemGenics in stock-deal
- Monsanto licenses Incyte's line of databases
- Arris acquires Sequana Therapeutics in a $166mm stock swap
- SmithKline in $125 million deal with Human Genome Sciences
- Incyte agrees to acquire Synteni in all stock transaction
- Sandoz signs licensing agreement with Scripps Research Instit
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.